Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Vaxelis vs PedvaxHIB in AI/AN Infants
NCT04978818Phase 4Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of DTaP-IPV-Hep B-PRP-T vaccine in Haemophilus influenzae type b infection (Hib) (2 arms), sponsored by Johns Hopkins Bloomberg School of Public Health. Primary endpoint: Anti-PRP IgG Geometric Mean Concentration. Started Jan 2022; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT04978818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978818.